oxprenolol with cyclopenthiazide and with placebo, in mild to moderate hypertensives . Those patients excluded were suffering from heart failure, asthma, cerebrovascular disease or severe depression. All patients were admitted to the ward and taught to record their own blood pressures. They were followed up at a special trial clinic where blood pressures were recorded by a trained nurse using a zero-muddler sphygmomanometer. The therapy was adjusted by a physician and blood pressures were taken in the supine and erect positions and after exercise. The courses consist of:-1. oxprenolol in adjustable dose with dummy thiazide; 2. cyclopenthiazide 0.5 mg. (with potassium), (2 Navidrex-K) plus dummy oxprenolol;
oxprenolol with cyclopenthiazide and with placebo, in mild to moderate hypertensives . Those patients excluded were suffering from heart failure, asthma, cerebrovascular disease or severe depression. All patients were admitted to the ward and taught to record their own blood pressures. They were followed up at a special trial clinic where blood pressures were recorded by a trained nurse using a zero-muddler sphygmomanometer. The therapy was adjusted by a physician and blood pressures were taken in the supine and erect positions and after exercise. The courses consist of:-1. oxprenolol in adjustable dose with dummy thiazide; 2. cyclopenthiazide 0.5 mg. (with potassium), (2 Navidrex-K) plus dummy oxprenolol;
3. dummy oxprenolol plus dummy thiazide.
Each patient received three 12-week courses in random order separated by four week wash-out periods.
A starting dose of 960 mg. daily was tried in order to gain rapid control, but was found to be associated with unacceptable side effects. We now start with a small dose and increase it gradually. Forty patients are now in the trial and 41 treatment courses have been completed (oxprenolol 13, cyclopenthiazide with potassium 15, placebo 13).
Oxprenolol caused reduction of blood pressure in 11 of the 13 patients (mean 28.3 mm, Hg systole and 10.7 mm. Hg diastole). with 7 patients being controlled (i.e. a diastolic pressure less than 95 mm. Hg).
Cyclopenthiazide caused reduction in 11 and increase in 2 out of 15 patients (mean reduction 18.7 mm. Hg systole and 7.5 mm. Hg diastole). Placebo response was mixed, with an insignificant mean change.
Weight increase was noted in patients while taking oxprenolol and placebo and a decrease in patients on thiazide. Side effects were mainly gastro-intestinal, but tinnitus was noted by some on high dosage. No cases of bradycardia, heart failure or asthma have been seen.
These preliminary results are very encouraging and we are continuing the trial. We have shown that oxprenolol reduces blood pressure in most hypertensives and control can be achieved without adding other drugs.
Additional studies in two patients using the Oxford 24-hour direct recording instrument suggest that big over-swings of blood pressure may follow once daily doses of oxprenolol, and it seems that the tablets will have to be taken at least twice daily for smooth control. It is common practice in the treatment of hypertension to use drug combinations, both to improve the efficacy of pressure control and to ameliorate side effects. The present trial was designed to test the combined effects of guanethidine and oxprenolol in lowering blood pressure. The design was such that a synergistic, additive or antagonistic effect could be ascertained.
Description of trial
Patients were initially stabilised on guanethidine to achieve lying diastolic blood pressure levels of approximately 110 mm. Hg. Each patient then entered four randomly allocated treatment periods, when they were given either guanethidine alone, placebo, oxprenolol or a combination of oxprenolol and guanethidine. Patients took tablets identical in appearance, number and time of dosing throughout the trial.
Each treatment period lasted 6 weeks. A fixed dose of oxprenolol (40 mg. three times daily for 2 weeks then 80 mg. three times daily for 4 weeks) was used in the oxprenolol and oxprenolol plus guanethidine. The dose of guanethidine initially employed for stabilisation was continued.
Patients were seen at 2-weekly intervals. Parameters examined were: blood pressure measured with a Hawksley (muddled zero) sphygmomanometer in the lying and standing positions and after standard exercise, pulse rate, weight, forced expiratory volume, standard haematological and biochemical screening tests, plasma oxprenolol concentrations and response to isoprenaline infusion.
Results
Thirteen patients were selected for study. None had a history of congestive failure or obstructive airways disease. All had retinal grade I or II. Blood urea was < 40 mg. %in all cases. One patient was withdrawn when he developed transient neurological signs while poorly controlled in the placebo period. Three patients failed to comply with the protocol. The data from the remaining 9 were analysed.
The average presenting untreated lying blood pressure was 203/120 rom. Hg, and prior to entry into the trial 172/101 mm. Hg (i.e. when stabilised on guanethidine alone). The mean of the last 2 measurements in each period were analysed. The results are shown in Table I .
Analysis of variance to determine the effect of guanethidine, oxprenolol and any interaction between the two drugs showed a significant reduction in systolic and diastolic standing and exercise blood pressures and lying diastolic blood pressures for both drugs at the 5% level. Oxprenolol in addition produced a reduction in lying systolic blood pressure. There was no evidence of any interaction between the effects of these 2 drugs. There were no significant changes in weight or forced expiratory volume. Pulse rate was significantly reduced by oxprenolol. The relationship between plasma oxprenolol concentrations and shift in isoprenaline response remain to be analysed.
Conclusions
It has been shown that there is an additive but no synergistic effect of the combination of guanethidine and oxprenolol. In the patients studied, the combination was effective and acceptable. 
